OncoZenge AB (publ)

Stockholm Stock Exchange ONCOZ.ST

OncoZenge AB (publ) Net Income for the year ending December 31, 2023: USD -1.57 M

OncoZenge AB (publ) Net Income is USD -1.57 M for the year ending December 31, 2023, a 64.77% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

OncoZenge AB (publ) Net Income for the year ending December 31, 2022 was USD -4.45 M, a -941.18% change year over year.
OncoZenge AB (publ) Net Income for the year ending December 31, 2021 was USD -427.85 K.

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Net Income Margin

Stockholm Stock Exchange: ONCOZ.ST

OncoZenge AB (publ)

CEO	Mr. Stian Kildal
IPO Date	Feb. 12, 2021
Location	Sweden
Headquarters	Gustavslundsvagen 34
Employees	2
Sector	Healthcare
Industries Biotechnology Clinical Trials Cosmetics Dental Care Drugstores & Retail Pharmacies Mental Health Personal Care Pharmaceuticals

Description

OncoZenge AB (publ), a pharmaceutical company, develops healthcare products for cancer supportive care. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of oral mucositis. The company was founded in 2020 and is headquartered in Bromma, Sweden. OncoZenge AB (publ) is a subsidiary of Moberg Pharma AB (publ).

Key trends

Past 5 years